Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Newsletter subscription
Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Languages
ENGLISH
English (US)
ASIAN
Монгол
日本語
Tiếng Việt
Bahasa Indonesia
中文 (简体, 中国大陆)
EUROPEAN
Русский
Español (España)
Français (France)
MIDDLE_EAST_AFRICA
العربية
Search results for "GLP-1"
Home
To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why
As the adoption of GLP-1 receptor agonist obesity medications such as Wegovy and Mounjaro accelerates, medical experts are calling for structured...
09/23/2026, 22:29 ET
Does Wegovy Triple Depression Risk? Real-World Data from Korean Hospitals Yields Nuanced Findings
A recent observational study indicates that individuals taking popular GLP-1 receptor agonist obesity medications may face an elevated risk of...
09/15/2026, 10:34 ET
Can Eggs and Olive Oil Help You Lose Weight? Why the "Natural Wegovy" Trend Can Backfire
A viral diet trend touting olive oil drizzled over boiled eggs as a "natural Wegovy" has gained traction among...
09/15/2026, 10:17 ET
Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports
GLP-1 (glucagon-like peptide-1) class medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, are...
09/01/2026, 21:54 ET
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide
JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s...
08/22/2026, 20:13 ET
'Natural Wegovy' Is a Myth, Surgeon Warns, Pushing Back on Viral Diet Trend
A viral social media trend promoting a "Natural Wegovy" diet—eating boiled eggs drizzled with olive oil—has prompted a...
08/21/2026, 04:13 ET
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care
Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE.
08/03/2026, 09:55 ET
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
07/27/2026, 05:31 ET
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...
07/22/2026, 03:25 ET
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
07/20/2026, 19:27 ET
1
2
3
Next